Added to YB: 2025-08-11
Pitch date: 2025-08-07
NVO [bullish]
Novo Nordisk A/S
+1.68%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 315.86
Price Target
N/A
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
value
Novo Nordisk: A High-Margin Compounder Hiding in Plain Sight
NVO: Established diabetes/GLP-1 leader with 25yr expertise in complex protein chemistry. Trading at 12-14x earnings vs LLY's 60x. Transparent operations, ethical trials reporting, foundation owns 28% ensuring stability. Proven ability to innovate past patent expiries like insulin. Obesity/diabetes market large enough for duopoly with LLY.
Read full article (2 min)